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Purpose: There is no standard of care for recurrent high-grade glioma. Treatment strategies include reresection, reirradiation, systemic
agents, intratumoral thermotherapy using magnetic iron-oxide nanoparticles (“nanotherapy”), and tumor treating fields. Only a small
number of patients are eligible for reresection, and because many patients receive a full course of radiation therapy, there is fear of
reirradiation-induced morbidity. Modern radiation techniques have resulted in greater acceptance of reirradiation. In this work we
retrospectively analyzed patients who had undergone reirradiation of high-grade glioma at Charité Universitätsmedizin Berlin.
Methods and Materials: All patients treated with reirradiation for recurrent high-grade glioma in our department from January 1997 to
February 2014 were analyzed in this study. In total, 198 patients were included. The primary endpoint was overall survival after
recurrence.
Results: One hundred ninety-eight patients were identified. Median time from first radiation therapy to reirradiation was 14 months.
Median follow-up from the first day of reirradiation to last contact or death was 7 months. Median overall survival after relapse was 7
months for the overall cohort. For glioblastoma, median overall survival after relapse was 6 months and for grade 3 gliomas 14 months.
Treatment was generally well tolerated. Common Terminology Criteria for Adverse Events grade 3 toxicity was observed in 5.1%
patients and grade 4 toxicity in 2.5%. No patient developed grade 5 toxicity. The likelihood of developing severe toxicity (Common
Terminology Criteria for Adverse Events grade 3 or 4) was not significantly higher in the group of patients who received reirradiation in
the first 14 months after initial radiation therapy. Patients who received a higher biologically effective dose to the tumor also did not
have a significantly higher rate of severe acute toxicity.
Conclusions: The prognosis of recurrent high-grade glioma remains dismal. Reirradiation is often tolerable even after early recurrence
(<14 months) and with higher doses (eg, 49.4 Gy/3.8 Gy) in selected patients.
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Despite the use of multimodal approaches, treatment of
high-grade glioma remains a challenge, and the prognosis
is dismal.1,2 Ultimately, almost every patient shows
relapse; most sites of relapse are found within close
proximity to the original tumor bed.3 However, to date,
there is no standard of care for this condition. Reresection
may be considered depending on the performance status
and tumor localization, but morbidity is higher than that
in the initial surgery, and only a small subgroup of pa-
tients is eligible.4 Other treatment strategies include reir-
radiation, unconventional temozolomide regimens and
other systemic agents like bevacizumab, intratumoral
thermotherapy using magnetic iron-oxide nanoparticles
(“nanotherapy”), external radiofrequency approaches and
tumor treating fields.5,6 Because almost all patients with
recurrent glioma receive a full course of radiation therapy,
there is a legitimate fear of reirradiation-induced
morbidity. Modern radiation techniques like fractionated
stereotactic radiation therapy (FSRT) allow for an
improved therapeutic ratio and better sparing of organs at
risk (OARs) and have thus led to greater acceptance of
reirradiation. However, dose constraints for normal brain
tissue remain unclear. It is known from in vivo experi-
ments that repair of irradiation-induced cell damage is
dependent on fraction size, cumulative dose, and time
between first and second course of irradiation.7 Most
published studies on FSRT reirradiation in high-grade
glioma so far have used hypofractionated regimens (5
Gy per fraction).8,9 Hypofractionation does shorten
treatment time in a group of patients with highly impaired
life expectancy but is associated with a potentially
increased late toxicity rate. An alternative could be
accelerated hyperfractionation, an approach that would
offer short treatment times and a lower risk of late toxicity
combined with the theoretical advantage of lower tumor
repopulation in treatment intervals.
In this study, we have retrospectively analyzed 198
patients with high-grade glioma treated with reirradiation
at Charité Universitätsmedizin Berlin. The primary
endpoint was overall survival (OS). Results were
compared with the published data on patients who
received reirradiation and systemic therapy.Methods and Materials
Treatment decisions, patient selection, and dose
regimens
This retrospective analysis was approved by the insti-
tutional review board. Written informed consent was ac-
quired from all patients with respect to radiation therapy
(RT) treatment and clinical data management for researchpurposes. All patients treated with reirradiation for recurrent
glioma in our department from January 1997 to February
2014 were analyzed in this study. A total of 198 patients
were included. The primary endpoint of OS was chosen
because analysis of progression-free survival is prone to
error in glioma cohorts owing to pseudoprogression.
Stratification, variables, and follow-up
Patients were stratified according to fractionation
scheme, age, sex, Karnofsky Performance Status (KPS),
extent of surgery (biopsy, partial resection, or gross total
resection), O-6-methylguanine-DNA methyltransferase
(MGMT) status, tumor localization (frontal, parietal,
temporal, occipital, or central), chemotherapy at recur-
rence, whether they had received nanotherapy, histology
at recurrence, and planning target volume (PTV). For
patients who did not receive neurosurgical intervention
when recurrence occurred, we assumed the same histol-
ogy at recurrence as at initial diagnosis.
Follow-up examinations, including magnetic reso-
nance imaging (MRI) and clinical and neurologic exam-
inations, were performed at a 6- to 8-week interval after
radiation therapy and then every 3 months.
RT treatment planning
Contrast agenteenhanced computed tomography in a
thermoplastic mask and gadolinium-enhanced MRI were
performed before RT planning. Target volumes were
based on current MRI (not older than 4 weeks). In patients
who had undergone reresection, the gross tumor volume
was defined as the summation of the postoperative sur-
gical cavity with or without residual tumor lesion(s) and
tumor extension on the preoperative T1-weighted
gadolinium-enhanced imaging. In patients who had not
undergone reresection, the gross tumor volume was
defined as tumor extension on the preoperative T1-
weighted gadolinium-enhanced imaging. The size of the
clinical target volume (CTV) was individually decided
based on size of the initial PTV, tumor grade, time from
last RT to recurrence, as well as initially received dose.
CTVs varied between 0 and 2 cm. The extent of peritu-
moral edema was not routinely included in the CTV. For
the PTV, an additional margin of 0.1 to 0.5 cm was added
depending on the treatment and modality used for posi-
tion verification. Intensity modulated radiation therapy
was applied using a 6-MV linear accelerator with multi-
leaf collimators or the NovalisTM therapy system (Var-
ian; Brainlab, München, Germany).
For some patients, we provided accelerated hyper-
fractionation with 59.2 Gy/1.6 Gy 2 times a day when
OARs, such as the optic nerves, chiasm, or brain stem
would have been covered by the PTV and in cases where
the patient was willing and fit enough to undergo
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more likely to be used in patients with lower KPS.
Intratumoral thermotherapy using magnetic iron-
oxide nanoparticles
Between 2007 and 2009, a total of 32 patients received
neuronavigationally controlled intratumoral instillation of
an aqueous dispersion of iron-oxide (magnetite) nano-
particles and subsequent heating of the particles in an
alternating magnetic field in a prospective trial for
recurrent supratentorial glioblastoma (GBM) for patients
between 18 and 75 years with a KPS  60%.6 The
thermotherapy was performed using the alternating mag-
netic field applicator MFH 300F with integrated ther-
mometry unit (NanoActivator F100; MagForce
Nanotechnologies, Berlin, Germany). The magnetic fluid
MFL AS1 (NanoTherm AS1; MagForce Nanotechnol-
ogies), an aqueous dispersion of superparamagnetic
nanoparticles with an iron concentration of 112 mg/mL,
served as the energy transducer. The hyperthermia treat-
ment generally consisted of 6 semiweekly sessions, and
each thermotherapy session lasted 1 hour.
Toxicity
Retrospective analysis of long-term toxicity in recurrent
GBM patients is very error prone because symptoms can
either be attributed to the tumor itself or to tumor treatment
in a cohort of patients with a very limited life-expectancy.
Therefore, in this work only acute toxicity (90 days after
treatment) was analyzed according to Common Terminol-
ogy Criteria for Adverse Events (CTCAE 4.0). Toxicity
data were extracted from the digital patient files.
Formulas and statistics
OS was calculated from the first day of reirradiation
using Kaplan-Meier analysis and the Cox proportional
hazard model. A P value of less than .05 was considered
statistically significant. A P value of less than .1 was
considered a trend. All variables with a P value < .25 in
the univariable analysis were included in multivariable
analysis. All statistical analyses were performed using
IBM SPSS Statistics 19 (New York). We assumed an a/b-




Patient characteristics are presented in Table 1. One
hundred ninety-eight patients treated with radiationtherapy for glioma were identified in our retrospective
analysis. Median age at recurrence was 49 years. Median
time from the first RT to reirradiation was 14 months.
Median follow-up from the first day of reirradiation to last
contact or death was 7 months. Median OS after relapse
was 7 months for the entire cohort. For GBM (recurrent
and secondary), median OS was 6 months, and for all
grade 3 gliomas, OS was 14 months. Patients who
received nanotherapy showed a median overall survival
time of 6 months.
At last contact, 82.8% of patients had died. Of the
overall cohort, 126 patients were male and 72 were fe-
male. All patients had received a neurosurgical interven-
tion leading to the initial diagnosis. Of the total patients,
39.9% had received a surgical intervention at recurrence,
3% had received a biopsy, 8.1% partial resection, and
28.3% gross total resection; in 0.5% of the patients, the
result of the surgery was unknown. About two-thirds
(67.2%) of patients had been diagnosed with a recurrent
GBM and 9.6% of patients with a secondary GBM. The
majority of patients received FSRT (87.9%) and hypo-
fractionated reirradiation (74.7%). The most common
fractionation schemes were 41.8 Gy/3.8 Gy and 49.4 Gy/
3.8 Gy. The range of single doses was 1.2 to 6.25 Gy, the
range of total doses was 11.4 to 73 Gy, the range of
BED9.32 was 15.22 to 82.4 Gy.Toxicity
Data on toxicity are presented in Table 2. Treatment
was overall well tolerated. About one-third of patients
(31.3%) developed minor toxicity (grade 1-2), which
mainly resulted in dermal side effects and mild neurologic
side effects like headache. Of the total patients, 5.1%
developed grade 3 toxicity and 2.5% developed grade 4
toxicity. No patient developed acute grade 5 toxicity. The
likelihood of developing severe toxicity (CTCAE grade 3/
4) was not higher in the group of patients who received
reirradiation in the first 14 months (median interval) after
initial RT (P Z .89). In addition, patients who received
higher BED9.32 ( vs < median of 58.8 Gy) did not have
a significantly higher rate of severe acute toxicity (P Z
.06).Overall survival and prognostic factors
Analysis of potential prognostic factors is shown in
Table 3. Positive predictors of survival in univariable
analysis were younger age, higher KPS, grade III tumor at
recurrence instead of grade IV tumor, and higher BED9.32
to the PTV. In multivariable analysis, only younger
age and higher KPS remained significant positive pre-
dictors. Sex; MGMT status; gross total resection; appli-
cation of chemotherapy, nanotherapy, or accelerated
Table 1 Characteristics of the 198 glioma patients
Overall cohort
(n Z 198)
Median age at recurrence
(min/max), [y]
49 9/79




Mean PTV  SD [ccm]
at recurrence
61.9  63.7
Median BED provided at














Brain stem 2 1.0





Extent of surgery at recurrence
No surgery 119 60.1
Biopsy 6 3.0
Partial resection 16 8.1
Gross total resection 56 28.3

















Recurrent glioblastoma 133 67.2
Secondary glioblastoma 19 9.6
Recurrent astrocytoma grade 3 28 14.1
Secondary astrocytoma grade 3 8 4.0
Recurrent oligoastrocytoma grade 3 3 1.5
(continued on next page)
Table 1 (continued )
n %
Recurrent oligodendroglioma grade 3 1 0.5






Fractionation schema at recurrence
Normofractionation 31 15.7
Accelerated hyperfractionation 14 7.1
Hypofractionation 148 74.7











Abbreviations: FSRT Z fractionated stereotactic radiation therapy;
KPS Z Karnofsky Performance Status; MGMT Z O-6-
methylguanine-DNA methyltransferase; n/a Z not applicable; PTV
Z planning target volume; tmz Z temozolomide.
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did not affect survival.
Discussion
To our knowledge, this study included the second
largest single-institution cohort of reirradiated patients
after the cohort in the study published by Palmer et al in
2015.11 In multivariable analysis, only age and KPS were
significant prognostic factors. Age is a well-established
factor in the literature and is used in prognostic indices
for predicting outcome in recurrent glioma.12-14 The
prognostic role of KPS has been well established among
other authors by Niyazi et al.14
Because only a minority of patients undergo surgical
intervention at recurrence, the correct grading forTable 2 Acute toxicity within the first 90 days after radi-
ation therapy according to Common Terminology Criteria for
Adverse Events version 4.0
n %
None 98 49.5
Grade 1 and 2 62 31.3
Grade 3 10 5.1
Grade 4 5 2.5
n/a 23 11.6
Abbreviation: n/a Z not applicable.
Table 3 Univariable and multivariable analysis of potential predictive factors of overall survival after relapse
Variable Univariable analysis Multivariable analysis
P HR 95% CI P HR 95% CI
Age (< vs  median of 49 y) < .001* 0.529 0.384-0.729 .006* 0.588 0.404-0.857
Sex (female vs male) .298 0.842 0.610-1.163
KPS ( vs < median of 70%) < .001* 0.366 0.255-0.525 < .001* 0.366 0.246-0.543
MGMT-status (methylated vs unmethylated) .559 0.778 0.336-1.804
Grading (3 vs 4) .001* 0.522 0.351-0.776 .287 0.789 0.509-1.221
Surgery (gross total resection vs no
surgery/biopsy/subtotal resection)
.6 1.094 0.782-1.531
Interval from initial RT to
reirradiation (14 vs <14)
.269 0.835 0.606-1.15





BED to tumor ( vs < median of 58.8 Gy) .02* 0.685 0.498-0.943 .201 0.785 0.541-1.138
Chemotherapy at recurrence (yes vs no) .991 0.998 0.726-1.372
Nanotherapy (yes vs no) .256 1.324 0.816-2.148
Abbreviations: BEDZ biologically effective dose; CI Z confidence interval; HR Z hazard ratio; KPSZ Karnofsky performance status; MGMTZ
O-6-methylguanine-DNA methyltransferase; PTV Z planning target volume.
* P value  .05.
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therefore, authors tend to evaluate the prognostic role of
grading at initial diagnosis.14,15 In the present work,
however, we chose to evaluate the role of histology at
recurrence (in patients with no surgical intervention, the
initial diagnosis was used) because we assumed that this
will reflect the biologic behavior of the recurrent tumor
more appropriately. However, tumor grade at recurrence
was only a prognostic factor in univariable analysis but
not confirmed in multivariable analysis. In an alternative
analysis where grading at initial diagnosis instead of
grading at recurrence was evaluated, significance was
observed in univariable analysis but was also not
confirmed in the multivariable model (data not shown).
Histologic grading at recurrence being a positive pre-
dictor in univariable analysis but not in multivariable
analysis can probably be explained by the low number of
grade 3 tumors (29.8%).
In our cohort, patients who received a higher BED9.32
showed better OS in the univariable analysis. This was
not confirmed for multivariable analysis. The effect on OS
in univariable analysis is most probably due to the fact
that patients with a high KPS were more likely to receive
higher doses. Patients who received higher BED9.32 did
not have a significantly higher rate of severe acute toxicity
(CTCAE grade 3/4), and the likelihood of developing
severe toxicity was not higher in the group of patients
who received reirradiation in the first 14 months (median
interval) after initial RT. To this date, there is no
consensus on the optimal reirradiation schema.16 Our data
suggest that careful dose escalation such as 49.4 Gy/3.8
Gy and early reirradiation are safe and tolerable inselected patients. Further work on the radiosensitivity of
preirradiated tissue is necessary to better understand the
limits of dose escalation, the role of new radiosensitizers
as well as on concomitant targeted therapy needs to be
further elucidated.
A small number of patients was treated using accel-
erated hyperfractionation, which is hypothesized to pre-
vent tumor repopulation in treatment intervals and reduce
late radiation injury.17 In our population, accelerated
hyperfractionation was not a prognostic factor for OS.
This is in accordance with our publication in which we
showed that accelerated hyperfractionation is not inferior
to normofractionation in primary GBM patients in a
retrospective setting.18 One might assume that accelerated
hyperfractionation is feasible in a carefully selected pa-
tient cohort with long life expectancy, good KPS, and
OARs in the PTV region.
In this work we showed a median overall survival after
relapse of 6 months for GBM patients who received ra-
diation therapy. This is comparable to published data on
reirradiated patients. Combs et al show a median overall
survival of 8 months in an observational series (n Z
59).15
Data on survival after GBM relapse without radiation
therapy is mostly available from prospective trials eval-
uating alternative treatment options and often involve
patients with a relatively high KPS: Friedman et al
showed median overall-survival times of 9.2 and 8.7
months for patients treated with Bevacizumab alone or in
combination with Irinotecan (n Z 167), only patients
with a KPS 70% were included.19 In a phase 2 trial of
Carmustine Brandes et al showed a median overall
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retrsopective series on treatment using Procarbazine,
Schmidt et al show median overall-survival time of 34.3
weeks (n Z 83).21 We assume that the slightly lower
survival times in our cohort can be attributed to relatively
high number of patients with low KPS.
Limitations
Our study had several limitations. First, data on the
MGMT status are missing in the majority of patients.
Second, no analysis of chronic toxicity was performed
because it is difficult to differentiate between chronic
toxicity and disease progression in patients with recurrent
high-grade glioma. Third, the number of patients treated
with nanotherapy or accelerated hypofractionation may
have been too low to identify significant differences in
OS. Fourth, there is a high degree of heterogeneity in
terms of CTV and PTV margins, and it is possible that
smaller margins lead to a higher risk of marginal misses in
the respective patients. Fifth, there is a great variability in
terms of fractionation regimens, which might affect our
results, even though uni- and multivariable analyses do
not suggest so.
Conclusions
The prognosis of recurrent high-grade glioma remains
dismal. Reirradiation is often feasible even after early
recurrence (<14 months) and with higher doses (BED9.32
> of 58.8 Gy, eg, 49.4 Gy/3.8 Gy) in carefully selected
patients.
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